WO2007149052A1 - Novel polypeptides for anti-viral treatment - Google Patents
Novel polypeptides for anti-viral treatment Download PDFInfo
- Publication number
- WO2007149052A1 WO2007149052A1 PCT/SG2007/000168 SG2007000168W WO2007149052A1 WO 2007149052 A1 WO2007149052 A1 WO 2007149052A1 SG 2007000168 W SG2007000168 W SG 2007000168W WO 2007149052 A1 WO2007149052 A1 WO 2007149052A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- giy
- cys
- pro
- tht
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 283
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 268
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 266
- 238000011282 treatment Methods 0.000 title claims abstract description 27
- 230000000840 anti-viral effect Effects 0.000 title abstract description 11
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 70
- 206010012310 Dengue fever Diseases 0.000 claims abstract description 31
- 208000001490 Dengue Diseases 0.000 claims abstract description 25
- 208000025729 dengue disease Diseases 0.000 claims abstract description 25
- 230000003612 virological effect Effects 0.000 claims abstract description 22
- 230000004927 fusion Effects 0.000 claims description 68
- 238000003776 cleavage reaction Methods 0.000 claims description 46
- 230000007017 scission Effects 0.000 claims description 42
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 33
- 108091005804 Peptidases Proteins 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 32
- 108010013369 Enteropeptidase Proteins 0.000 claims description 31
- 102100029727 Enteropeptidase Human genes 0.000 claims description 31
- 150000001413 amino acids Chemical class 0.000 claims description 29
- 102000040430 polynucleotide Human genes 0.000 claims description 28
- 108091033319 polynucleotide Proteins 0.000 claims description 28
- 239000002157 polynucleotide Substances 0.000 claims description 28
- 239000004365 Protease Substances 0.000 claims description 27
- 239000000872 buffer Substances 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 11
- 238000011321 prophylaxis Methods 0.000 claims description 8
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims description 6
- 201000005807 Japanese encephalitis Diseases 0.000 claims description 6
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 6
- 201000005805 Murray valley encephalitis Diseases 0.000 claims description 6
- 208000003152 Yellow Fever Diseases 0.000 claims description 6
- 238000013456 study Methods 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 208000004006 Tick-borne encephalitis Diseases 0.000 claims description 4
- 229960003067 cystine Drugs 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical class C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 5
- 101100129088 Caenorhabditis elegans lys-2 gene Chemical group 0.000 claims 1
- 101100455752 Caenorhabditis elegans lys-3 gene Chemical group 0.000 claims 1
- 101100289888 Caenorhabditis elegans lys-5 gene Chemical group 0.000 claims 1
- 101150118523 LYS4 gene Chemical group 0.000 claims 1
- 108010022999 Serine Proteases Proteins 0.000 abstract description 2
- 102000012479 Serine Proteases Human genes 0.000 abstract description 2
- 229940121357 antivirals Drugs 0.000 abstract description 2
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 40
- 102000004169 proteins and genes Human genes 0.000 description 36
- 235000018102 proteins Nutrition 0.000 description 32
- 102000035195 Peptidases Human genes 0.000 description 27
- 235000001014 amino acid Nutrition 0.000 description 25
- 229940024606 amino acid Drugs 0.000 description 24
- 125000003275 alpha amino acid group Chemical group 0.000 description 22
- 235000019419 proteases Nutrition 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 238000000746 purification Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 102000002933 Thioredoxin Human genes 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 108060008226 thioredoxin Proteins 0.000 description 15
- 229940094937 thioredoxin Drugs 0.000 description 15
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 14
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N Glutamine Chemical group OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 238000004007 reversed phase HPLC Methods 0.000 description 13
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 238000000926 separation method Methods 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 10
- 241000894007 species Species 0.000 description 10
- -1 GIy Chemical class 0.000 description 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 150000007523 nucleic acids Chemical group 0.000 description 9
- 238000000108 ultra-filtration Methods 0.000 description 9
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 239000000376 reactant Substances 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- 108060002063 Cyclotide Proteins 0.000 description 7
- 125000005647 linker group Chemical group 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 238000003614 protease activity assay Methods 0.000 description 5
- 108010069514 Cyclic Peptides Proteins 0.000 description 4
- 102000001189 Cyclic Peptides Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- DEOKFPFLXFNAON-UHFFFAOYSA-N N-α-Benzoyl-DL-arginine 4-nitroanilide hydrochloride Chemical compound Cl.C=1C=C([N+]([O-])=O)C=CC=1NC(=O)C(CCCN=C(N)N)NC(=O)C1=CC=CC=C1 DEOKFPFLXFNAON-UHFFFAOYSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 229960002433 cysteine Drugs 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 235000019833 protease Nutrition 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 108010000350 dengue virus NS3 protease Proteins 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 210000003000 inclusion body Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 210000000605 viral structure Anatomy 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 2
- 241000725619 Dengue virus Species 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 108010074860 Factor Xa Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108060005987 Kallikrein Proteins 0.000 description 2
- 102000001399 Kallikrein Human genes 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108090000787 Subtilisin Proteins 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 125000000837 carbohydrate group Chemical group 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- QPJDMGCKMHUXFD-UHFFFAOYSA-N cyanogen chloride Chemical compound ClC#N QPJDMGCKMHUXFD-UHFFFAOYSA-N 0.000 description 2
- WPBXOELOQKLBDF-UHFFFAOYSA-N cyanogen iodide Chemical compound IC#N WPBXOELOQKLBDF-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000010217 densitometric analysis Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
- 208000021760 high fever Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229920002704 polyhistidine Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 241001147422 tick-borne encephalitis virus group Species 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 230000003191 uterotonic effect Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101000583080 Bunodosoma granuliferum Delta-actitoxin-Bgr2a Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000145843 Chassalia parvifolia Species 0.000 description 1
- 108090000746 Chymosin Proteins 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N Cyclohexanecarboxylic acid Natural products OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 description 1
- 108700005835 Dengue virus nonstructural protein 2B Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 229930195710 D‐cysteine Natural products 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- FFFHZYDWPBMWHY-UHFFFAOYSA-N HOMOCYSTEINE Chemical compound OC(=O)C(N)CCS FFFHZYDWPBMWHY-UHFFFAOYSA-N 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010002231 IgA-specific serine endopeptidase Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 1
- 102400001103 Neurotensin Human genes 0.000 description 1
- 101800001814 Neurotensin Proteins 0.000 description 1
- 101800001030 Non-structural protein 2A Proteins 0.000 description 1
- 101800001020 Non-structural protein 4A Proteins 0.000 description 1
- 101800001019 Non-structural protein 4B Proteins 0.000 description 1
- 101800000440 Non-structural protein NS3A Proteins 0.000 description 1
- 241000157511 Oldenlandia Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108010030544 Peptidyl-Lys metalloendopeptidase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- AFVLVVWMAFSXCK-VMPITWQZSA-N alpha-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(\C#N)=C\C1=CC=C(O)C=C1 AFVLVVWMAFSXCK-VMPITWQZSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000004918 carbon fiber reinforced polymer Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- BOOQTIHIKDDPRW-UHFFFAOYSA-N dipropyltryptamine Chemical compound C1=CC=C2C(CCN(CCC)CCC)=CNC2=C1 BOOQTIHIKDDPRW-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 150000004662 dithiols Chemical group 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- YVKSGVDJQXLXDV-BYPYZUCNSA-N ethyl (2r)-2-amino-3-sulfanylpropanoate Chemical compound CCOC(=O)[C@@H](N)CS YVKSGVDJQXLXDV-BYPYZUCNSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000012617 force field calculation Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000854 inhibitional effect Effects 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- MCYHPZGUONZRGO-VKHMYHEASA-N methyl L-cysteinate Chemical compound COC(=O)[C@@H](N)CS MCYHPZGUONZRGO-VKHMYHEASA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108010066533 ribonuclease S Proteins 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000029302 virus maturation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/56—Protease inhibitors from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This present invention generally relates to novel polypeptides for use in anti-viral treatment of human diseases.
- cyclic polypeptides exhibit biological activities ranging from uterotonic activity, anti-HIV property, neurotensin inhibition, and antimicrobial activity to insecticidal activity. Particularly well-known are the uterotonic activity of kalata Bl isolated from Oldenlandia qffinis and the anti-HIV activity of circulins isolated from Chassalia parvifolia K. Schum.
- the traditional use of herbs containing such cyclic polypeptides as indigenous medicine for a range of medical conditions has led to the isolation and identification of the cyclotide polypeptide family (Gran et al., (2000) J Ethnopharmacol.70(3): 197-203).
- Cyclotides are disulphide-rich proteins with the unusual features of a cyclic backbone and a cystine knot topology.
- a protein motif consists of three conserved disulphide bonds, two of which form an embedded ring in the structure that is penetrated by the third disulphide bond.
- detailed structural studies based on NMR data on kalata Bl revealed that the six cysteine residues in this 29-mer polypeptide form three disulphide bridges that link up the head-to-tail cyclic backbone into the uniquely folded structure designated as a cyclic cystine knot (CCK) (Craik et al. (1999) J MoI Biol. 294(5): 1327-36).
- CCK cyclic cystine knot
- cyclotides may provide a molecular framework for drug delivery in anti- viral treatment such as in anti-dengue treatment.
- anti- viral treatment such as in anti-dengue treatment.
- No report has however been made on any natural cyclotide having inhibitory activity against the dengue virus.
- the potential of such an application therefore relies on the use of molecular design to introduce new structural features or sequences into the cyclotide molecular framework, thereby generating new biological activities in the molecules.
- the basis for any design in turn relies on an in-depth understanding of mechanisms of viral infection and replication as well as structure- function relationships of the resulting molecules.
- Dengue is a mosquito-borne infection, the global prevalence of which has grown dramatically in recent decades. Found in tropical and sub-tropical regions around the world, the disease is now endemic in more than 100 countries in Africa, the Americas, the Eastern Mediterranean, South-east Asia and the Western Pacific. In Singapore, there are about 4000-5000 reported cases of dengue fever or dengue haemorrhagic fever every year. As of October 2005, Singapore reported 12,700 cases in the year with at least 19 deaths (Ministry of Health, Singapore). Other recent dengue outbreaks in South East Asia include the 21,537 cases with 280 dead in the Phillipines (January - October 2005), the 7200 infections in Thailand with at least 12 dead (May 2005), Indonesia's 80,000 infections with 800 deaths (2004) and the 33,203 cases in Malaysia (January 2005).
- Dengue haemorrhagic fever is a potentially deadly complication characterized by high fever, haemorrhagic phenomena—often with enlargement of the liver—and in severe cases, circulatory failure.
- Dengue virus contains a single positive-stranded RNA genome, which is first translated into a polypeptide that is then processed by host cell proteases and the virus- encoded NS3 protease to generate three structural and seven non-structural viral proteins.
- Optimal activity of the NS3 protease is essential for maturation of the virus, and while it has been shown to exhibit activity independently with some model substrates for serine proteases, its activity is markedly enhanced when coupled to NS2B (Yusof et al, (2000) J. Biol. Chem. 275:9963-9969). Accordingly, inhibition of NS3 offers the prospect of an effective anti-viral therapy for dengue fever, particularly in severe cases such as those of DHF and dengue shock .syndrome.
- cleavage recognition sites for the NS3 protease comprise a pair of positively charged dibasic amino acids (such as Arg or Lys) at the Pl and P2 positions, followed by a short-chain amino acid (such as GIy, Ala, Asp or Ser) at the Pl' site.
- Table 1 shows cleavage recognition sites of the NS3 protease in the NS2A/NS2B, NS2B/NS3, NS3A/NS4A and NS4B/NS5 regions of the viral polypeptide for dengue, Japanese encephalitis, Kunjin, Murray Valley encephalitis, yellow fever, West Nile, tick-borne encephalitis viruses.
- Inhibitors for the NS3 protease may be synthetic polypeptides mimicking uncleavable recognition sequences of the native polypeptide sites, or synthetic polypeptides with cleaved recognition sequences that bind the protease to prevent it from processing other polypeptide substrate molecules.
- the optimal activity of such polypeptides is often dependent on their structural stability as well as pH and temperature conditions. Stabilization of such polypeptides against degradation before they can act on a target therefore presents a serious drug delivery problem.
- the inventors have designed a series of novel polypeptides comprising viral NS3 protease recognition sequence on a cyclic molecular framework.
- the backbone of said cyclic molecular framework is "open" with a nick at the viral NS3 protease recognition sequence, enabling the molecule to be recognized and bound by the protease to prevent it from processing other viral polypeptide substrate molecules. With inhibition of the protease, viral replication and maturation are thus inhibited.
- the cyclic conformation of the molecules provides structural stability against degradation.
- the cyclic conformation is maintained and stabilized by disulphide bonds.
- the disulphide. bonds are spontaneously formed during expression of the novel polypeptides as fusion polypeptides, thereby advantageously obviating the need for further cyclization steps.
- Efficacy of said novel polypeptides as dengue virus NS3 protease inhibitors in anti-dengue treatment may be measured either using commercially available protease activity assay kits modified for anti-dengue protease activity assay, or with assay methods developed by the inventors. Using these assay methods, efficacy of the novel polypeptides was advantageously shown to be higher than the "open" cyclic kalata Bl molecule.
- polypeptide comprising the following sequence of amino acids or analogues thereof:
- Xi is Ala, Asp, GIy, or Ser
- X 2 is Cys or GIy
- X 3 is Cys or GIy
- X 4 is Cys or GIy
- X5 is Arg, GIn or Lys
- Xe is Arg or Lys. According to a second aspect, there is provided a polypeptide comprising the following sequence of amino acids or analogues thereof:
- X 1 is Ala, Asp, GIy, or Ser
- X 2 is Cys or GIy
- X 3 is Cys or GIy
- X 4 is Arg, GIn or Lys.
- a polypeptide comprising an open cyclic backbone, said open cyclic backbone comprising the following sequence of amino acids or analogues thereof:
- Xi is Ala, Asp, GIy, or Ser
- Xz is Cys or GIy
- X 3 is Cys or GIy
- X4 is Cys or GIy
- X5 is Arg, GIn or Lys
- X 6 is Arg or Lys.
- a polypeptide comprising an open cyclic backbone, said open cyclic backbone comprising the following sequence of amino acids or analogues thereof:
- X 1 is Ala, Asp, GIy, or Ser
- X 2 is Cys or GIy
- X 3 is Cys or GIy
- X 4 is Arg, GIn or Lys.
- polypeptide of the first and third aspects comprises a sequence set forth in SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10 or SEQ ID NO. 11.
- polypeptide of the second and fourth aspects comprises the sequence set forth in SEQ BD NO. 12.
- the open cyclic backbone of the polypeptide of the third and fourth aspects comprises at least one disulphide bond.
- the open cyclic backbone may be in the form of a cystine knot.
- polypeptide comprising the following sequence of amino acids or analogues thereof:
- Xi is Ala, Asp, GIy, or Ser
- X 2 is Cys or GIy
- X3 is Cys or GIy
- X4 is Cys or GIy
- X5 is Arg, Gin or Lys X 6 Is Arg or Lys, wherein said polypeptide is capable of inhibiting viral NS3 protease.
- a polypeptide comprising an open cyclic backbone, said open cyclic backbone comprising the following sequence of amino acids or analogues thereof:
- Xi is Ala, Asp, GIy, or Ser
- X 2 is Cys or GIy
- X 3 is Cys or GIy
- X 4 is Arg, GIn or Lys, wherein said polypeptide is capable of inhibiting viral NS3 protease.
- a functional equivalent of the polypeptide of the first, second, third, fourth, fifth or sixth aspects which retains the inhibitory activity of the reference polypeptide.
- the functional equivalent has at least 60% sequence identity with a polypeptide selected from the group consisting of SEQ ID NOS: 7, 8, 9, 10, 11 and 12. More preferably, the functional equivalent has at least 70%, 80% or 90% sequence identity with a polypeptide selected from the group consisting of SEQ ID NOS: 7, 8, 9, 10, 11 and 12.
- a polynucleotide comprising a sequence of nucleotides or analogues thereof which encodes a polypeptide of the first, second, third, fourth, fifth or sixth aspects.
- the polynucleotide may be in the form of RNA or DNA.
- the polynucleotide of the seventh aspect comprises the sequence set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 or combinations thereof.
- a recombinant vector comprising a polynucleotide of the seventh aspect.
- a host cell transformed with the recombinant vector of the eighth aspect.
- a method of producing a polypeptide of the first, second, third, fourth, fifth or sixth aspects comprising the step of culturing a host cell of the ninth aspect under conditions which permit expression of said polypeptide.
- compositions for treatment or prophylaxis of a NS3 protease-related condition in a subject comprising a polypeptide of the first, second, third, fourth, fifth or sixth aspect, and a pharmacologically acceptable carrier, excipient or diluent.
- the carriers, diluents and adjuvants must be "acceptable” in terms of being compatible with the other ingredients of the composition, and not deleterious to the recipient thereof.
- pharmaceutically acceptable carriers, excipients or diluents are demineralised or distilled water; saline solution; vegetable based oils such as peanut oil, safflower oil, olive oil, cottonseed oil, maize oil, sesame oils, arachis oil or coconut oil; silicone oils, including polysiloxanes such as methyl polysiloxane, phenyl polysiloxane and methylphenyl polysolpoxane; volatile silicones; mineral oils such as liquid paraffin, soft paraffin or squalane; cellulose derivatives such as methyl cellulose, ethyl cellulose, carboxymethylcellulose, sodium carboxymethylcellulose or hydroxypropylmethylcellulose; lower alkanols, for example ethanol or iso-propanol; lower aralkanols; lower polyal
- the NS3 protease related condition is selected from the group consisting of dengue, Japanese encephalitis, Kunjin viral disease, Murray Valley encephalitis, yellow fever, West Nile disease and tick-borne encephalitis.
- the subject may be a human.
- a polypeptide of the first, second, third, fourth, fifth or sixth aspect in the manufacture of a medicament for the treatment or prophylaxis of a NS3 protease related condition.
- the NS3 protease related condition may be selected from the group consisting of dengue, Japanese encephalitis, Kunjin viral disease, Murray Valley encephalitis, yellow fever, West Nile disease and tick- borne encephalitis.
- a polypeptide of the first, second, third, fourth, fifth or sixth aspect in the study, treatment or prophylaxis of a NS3 protease related condition, particularly dengue.
- a fourteenth aspect there is provided a method for treatment or prophylaxis of a NS3 protease related viral disease, comprising administering to a patient in need of such treatment a therapeutically effective dose of a composition of the eleventh aspect.
- a method for assaying the inhibitory activity of a polypeptide of the first, second, third, fourth, fifth or sixth aspect or a composition of the eleventh aspect comprising the steps of: a) incubating a mixture comprising a NS2B/NS3 fusion polypeptide containing a restriction protease cleavage recognition site and a buffer in the presence or absence of a polypeptide of the first, second, third, fourth, fifth or sixth aspect or a composition of the eleventh aspect; b) adding to said mixture a restriction protease capable of cleaving said NS2B/NS3 fusion polypeptide at the restriction protease cleavage recognition site to release the NS2B/NS3 polypeptide containing a NS3 cleavage recognition site; c) measuring the levels of uncleaved NS2B/NS3 polypeptide in the presence and absence of a polypeptide of the first, second, third, fourth, fifth, fifth or sixth aspect or a composition of the eleventh
- restriction protease refers to a proteolytic enzyme that cleaves polypeptides or proteins at specific recognition sequence sites.
- the restriction protease may be enterokinase, Factor Xa, thrombin, subtilisin, rennin, trypsin, chymotrypsin, kallikrein, TEV proteinase, Kex2 proteinase or collagenase. Li one embodiment, the restriction protease is enterokinase.
- kits for assaying the inhibitory activity of a polypeptide of the first, second, third, fourth, fifth or sixth aspect wherein the kit comprises a polypeptide of the first, second, third, fourth, fifth or sixth aspect.
- nucleic acid sequence refers to a nucleic acid the sequence of which has been obtained via back translation of a polypeptide, peptide or protein sequence, and synthesized using methods that are well known in the art.
- polynucleotide As used herein, the terms “polynucleotide”, “oligonucleotide”, “nucleic acid' and “nucleic acid molecule” refer to any homo- or hetero-polymer of ribonucleotides or deoxyribonucleotides of any length, that comprise natural, chemically or biochemically modified, non-natural, or derivatized nucleotide bases linked through phosphodiester bonds or modified phosphodiester bonds.
- the polynucleotide may be a single stranded molecule or a double stranded molecule of genomic or synthetic origin. Modified polynucleotides include methylated nucleotides and nucleotide analogues.
- sequence of nucleotides may be interrupted by non-nucleotide components.
- polynucleotide, oligonucleotide, nucleic acid and nucleic acid molecule further include complements, fragments and variants of the polynucleotide, oligonucleotide, nucleic acid and nucleic acid molecule, or analogues thereof.
- fusion polynucleotide refers to a polynucleotide comprising a plurality of regions. Plurality in this context means at least two.
- polypeptide refers to any polymer of amino acid residues (dipeptide or greater) linked through peptide bonds or modified peptide bonds and to variants and synthetic analogues of the same. Thus, these terms apply to naturally-occurring amino acid polymers as well as amino acid polymers in which one or more amino acid residues is a synthetic non-naturally occurring amino acid, such as a chemical analogue of a corresponding naturally occurring amino acid.
- Polypeptides of the present invention include, but are not limited to, products of chemical synthetic procedures, and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect and mammalian cells.
- polypeptides of the invention may comprise non-peptidic components, such as carbohydrate groups.
- Carbohydrates and other non-peptidic substituents may be added to a polypeptide by the cell in which the polypeptide is produced, and will vary with the type of cell.
- the nature and extent of the modifications in large part will be determined by the post-translational modification capacity of the particular host cell and the modification signals that are present in the amino acid sequence of the polypeptide in question. For instance, glycosylation patterns vary between different types of host cell.
- Polypeptides are defined herein, in terms of their amino acid backbone structures; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless, hi addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Proteins may be present as monomeric or as multimeric proteins e.g. as dimers (homo or heterodimers) or trimers.
- fusion polypeptide refers to a polypeptide having a plurality of regions, each corresponding to a distinct peptide. Fusion polypeptides can include linkers connecting the regions thereof.
- fusion protein as used herein, means a protein having a plurality of regions, each corresponding to a distinct peptide. Fusion proteins can include linkers connecting the regions thereof. Typically, for both fusion polypeptides and fusion proteins, while the plurality of regions are unjoined in their native state, they can be joined by their respective amino and carboxyl termini through a peptide linkage to form a single continuous polypeptide or protein. Plurality in this context means at least two.
- the linker is not part of the sequence of either the fusion partner as outlined below or the target polypeptide / protein.
- the linker is a short sequence of amino acids, for example about one to about 20 amino acids.
- the linker includes a cleavage recognition site for an enzymatic or chemical cleavage reagent as outlined below so that the fusion partner may be cleaved and purified away from the target polypeptide / protein.
- the linker may also include additional sequences inserted by one skilled in the art, for example, to provide sufficient spacing between the fusion partner and target polypeptide, or to facilitate cloning.
- Fusion partners may be used, which may include one or more additional amino acid sequences containing secretory or leader sequences, pro-sequences, or sequences which aid in, for instance detection, expression, separation or purification of the protein or to endow the protein with additional properties as desired such as higher protein stability, for example during recombinant production, or for instance to produce an immunomodulatory response.
- Examples of potential fusion partners include purification tags, such as a polyhistidine tag, epitope tags (short peptide sequences for which a specific antibody is available) and specific binding proteins; enzymes such as ribonuclease S, glutathione S-transferase, beta- galactosidase, luciferase and hemagglutinin; thioredoxin; a secretion signal peptide and a label, which may be, for instance, bioactive, radioactive, enzymatic or fluorescent, or an antibody.
- the target polypeptide / protein refers to the polypeptide / protein of the present invention.
- mutant and mutantation include any detectable change in genetic material, e.g. DNA, or any process, mechanism, or result of such a change. This includes gene mutations, in which the structure (e.g. DNA sequence) of a gene is altered, any gene or DNA arising from any mutation process, and any expression product (e.g. protein or enzyme) expressed by a modified gene or DNA sequence.
- open cyclic permutant of kalata Bl refers to a cyclic polypeptide having the same amino acid sequence as the naturally occurring kalata Bl but containing a nick.
- open cyclic permutant of kalata Bl differs from "open cyclic mutant(s) of kalata Bl” in that the latter refers to a nicked cyclic polypeptide having an amino acid sequence that is different (i.e. mutated) from the naturally occurring kalata BL
- variant refers to a polynucleotide or polypeptide that differs from a parent polynucleotide or polypeptide respectively, but retains essential properties.
- a typical variant of a polynucleotide differs in nucleotide sequence from another, parent polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the parent polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the parent sequence, as discussed below.
- a typical variant of a polypeptide differs in amino acid sequence from another, parent polypeptide. Generally, differences are limited so that the sequences of the parent polypeptide and the variant are closely similar overall and, in many regions, identical.
- a variant and parent polypeptide may differ in amino acid sequence by one or more substitutions, additions and deletions in any combination.
- a substituted or inserted amino acid residue may or may not be one encoded by the genetic code.
- analogue refers to a polynucleotide or a polypeptide which is a derivative of a parent polynucleotide or polypeptide respectively, which derivative comprises addition, deletion or substitution of one or more nucleotides or amino acids respectively, such that the polypeptide analogue retains substantially the same function as the parent polypeptide.
- derivative refers to a chemically or biologically modified version of the compound that is structurally similar to a parent compound. Derivatives of an amino acid include amino acids which are different from naturally-occurring amino acids and which have functions similar to those of the naturally- occurring amino acids.
- “Naturally-occurring amino acid” as used herein includes alanine (Ala), arginine (Arg), asparagine (Asn), aspartic acid (Asp), cysteine (Cys), glutamine (GIn), glutamic acid (GIu), glycine (GIy), histidine (His), isoleucine (He), leucine (Leu), lysine (Lys), methionine (Met), phenylalanine (Phe), proline (Pro), serine (Ser), threonine (Thr), tryptophan (Trp), tyrosine (Tyr), valine (VaI) and other amino acids which may or may not be found in proteins.
- derivatives of the naturally-occurring amino acid cysteine include D-cysteine, N-acetyl-L-cysteine, DL-homocysteine, L-cysteine methyl ester, L-cysteine ethyl ester, N-carbamoyl cysteine, glutathione and cysteamine.
- the term "functional equivalent” refers to a polypeptide that retains the biological activity of the parent polypeptide.
- the functionally-equivalent polypeptide may be homologous to the parent polypeptide or to a natural biological variant or an analogue thereof.
- Functional equivalents of the polypeptides may also include polypeptides in which relatively short stretches have a high degree of homology (at least 60%, 70%, 80%, 85%, 90%, 92%, 95% or 97%) with the parent polypeptide even though the overall homology between the two polypeptides may be much less. This is because important recognition or binding sites may be shared even when the general architecture of the polypeptide is different.
- biological activity refers to the inhibitory function of a polypeptide of the present invention, or to physiological responses that result upon administration of said polypeptide or a composition containing said polypeptide.
- Biological activity thus, encompasses therapeutic effects and pharmaceutical activity of such polypeptides and compositions.
- Biological activities may be observed in in vitro systems, designed to test or use such activities.
- Biological activity of a variant, analogue or functional equivalent of a polypeptide may be retained at the same or different level as the parent polypeptide, hi other words the variant, analogue or functional equivalent may be more or less active (or, of course, of similar or identical activity) as the parent polypeptide.
- NS3 related condition refers to a condition which is or can be caused, directly or indirectly, by the activity of the NS3 protease or of the NS3 protease when it is coupled to another viral component such as NS2B (i.e. NS2B/NS3).
- the term further includes a condition with which the NS3 protease, or the NS3 protease coupled to another viral component such as NS2B (i.e. NS2B/NS3), is in any way associated.
- treatment includes any and all uses which remedy a disease state or symptoms, prevent the establishment of disease, or otherwise prevent, hinder, retard, or reverse the progression of disease or other undesirable symptoms in any way whatsoever. Treatment may be effected prophylactically or therapeutically.
- anti-viral refers to a compound or a method that can inhibit viral infection of cells for example via inhibition of virus-induced cell-cell fusion, or to inhibit viral replication after infection.
- Viral infection may involve membrane fusion, as occurs in the case of enveloped viruses, or some other fusion event involving a viral structure and a cellular structure (e.g., such as the fusion of a viral pilus and bacterial membrane during bacterial conjugation).
- Viral replication may be inhibited by for example inhibition of viral enzymes required for replication (e.g., such as inhibition of the dengue NS3 protease that liberates individual viral peptides from the viral polypeptide precursor).
- the term "antiviral” further refers to a compound or a method that can reduce the likelihood of a person or animal contracting the viral disease upon exposure to potentially infective viral particles.
- terapéuticaally effective amount includes a non-toxic but sufficient amount of a compound to provide the desired therapeutic effect. _ The exact amount required will vary from subject to subject depending on factors such as the species being treated, the age and general condition of the subject, the severity of the condition being treated, the particular compound being administered and the mode of administration and so forth. Thus, it is not possible to specify an exact "effective amount”. However, for any given case, an appropriate "effective amount” may be determined by one of ordinary skill in the art using only routine experimentation.
- molecular framework refers to a polynucleotide or polypeptide molecule that provides rigid or semi-rigid structural and configurational support for a second polynucleotide or polypeptide molecule, such that the biological activity of the second polynucleotide or polypeptide is retained.
- cyclic when used in reference to a peptide, polypeptide or protein of the present invention refers to a peptide, polypeptide or protein that comprises cysteine residues or derivatives thereof at positions suitable for formation of at least one intramolecular disulphide bonds, and that has been folded into a cyclic conformation held together by said intramolecular disulphide bond(s).
- a cyclic peptide, polypeptide or protein of the present invention refers to a cyclic peptide, polypeptide or protein that contains an intrapeptide bond.
- This intrapeptide bond is preferably formed between the N-terminal amino group of the peptide and the C-terminal carboxy group of the peptide (referred to as "head-to-tail" cyclization), although peptides that have been cyclized by intrapeptide bond formation involving a side chain group(s) are also included.
- cyclic peptide, polypeptide or protein of the present invention refers to a cyclic peptide, polypeptide or protein that contains a nick in its cyclic amino acid backbone, preferably at a NS3 protease recognition site.
- purified means that the material in question has been removed from its natural or recombinant host, and associated impurities reduced or eliminated.
- object species is the predominant species present (ie., on a molar basis it is more abundant than any other individual species in the composition)
- substantially purified fraction is a composition wherein the object species comprises at least about 30 percent (on a molar basis) of all macromolecular species present.
- a substantially pure composition will comprise more than about 80 to 90 percent of all macromolecular species present in the composition.
- the object species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods such as Coomassie Brilliant Blue staining following SDS-PAGE analysis) wherein the composition consists essentially of a single macromolecular species.
- cleave and grammatical variations thereof refer to the chemical or enzymatic cutting of a polypeptide at specific amino acid sequence sites and the term “cleavage” includes scission or proteolysis in this invention.
- cleavage reagent refers to a reagent used to cleave a polypeptide at specific amino acid sequence sites, for example, to release a target polypeptide in a fusion polypeptide from its fusion partner.
- Suitable cleavage reagents include enzymes, such as proteases, and chemical reagents.
- the cleavage reagent is selected, taking into consideration the amino acid sequence of the polypeptide to be cleaved. Care must be taken that, if possible, the recognition sequence of the cleavage reagent for cleavage does not occur in a region other than in the intended cleavage region.
- Suitable specifically cleaving proteases are, for example, enterokinase, Factor Xa, thrombin, subtilisin, renin, collagenase, trypsin, chymotrypsin, endoproteinase Lys-C, kallikrein (Carter, P.: In: Ladisch, M. R.; Willson, R. C; Painton, C. C; Builder, S. E., eds., Protein Purification: From Molecular Mechanisms to Large-Scale Processes; ACS Symposium Series No. 427, American Chemical Society, pp. 181-193 (1990)), TEV proteinase (Parks, T. D., et al., Anal. Biochem.
- Suitable specifically cleaving chemical reagents include halogenated succinimides, cyanogen halides, hydroxylamines or combinations thereof.
- exemplary halogenated succinimides include N-chlorosuccinimide (NCS), N- iodosuccinimide (NIS) and N-bromosuccinimide (NBS).
- cyanogen halides include cyanogen chloride (CNCl), cyanogen iodide (CNI) and cyanogen bromide (CNBr). Conditions used for cleavage of a polypeptide will depend on the cleavage reagent used, and the conditions will be readily apparent to one skilled in the art.
- composition “comprising” means “including.” Variations of the word “comprising”, such as “comprise” and “comprises,” have correspondingly varied meanings. Thus, for example, a composition “comprising” X may consist exclusively of X or may include one or more additional components.
- range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within ; that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
- the term "about” as used in relation to a numerical value means, for example, +50% or +30% of the numerical value, preferably +20%, more preferably ⁇ 10%, more preferably still +5%, and most preferably +1%. Where necessary, the word "about” may be omitted from the definition of the invention.
- Figure 1 shows the nucleic acid and amino acid sequences of kalata Bl and its mutants.
- A The synthetic DNA sequence obtained by back translation based on the published amino acid sequence of kalata Bl (GenBank accession No.: 4F393825; GI: 15667740).
- B Amino acid sequence of thioredoxin fused to an open cyclic kalata Bl polypeptide. Residues 1 to 109 specifying thioredoxin are italicized. The polyhistidine tag is highlighted in bold.
- enterokinase recognition sequence is underlined and the arrow indicates the site of cleavage to yield the 29-amino acid open cyclic kalata Bl polypeptide with no unwanted residues
- C The enterokinase recognition sequence is underlined and the arrow indicates the site of cleavage to yield the 29-amino acid open cyclic kalata Bl polypeptide with no unwanted residues
- D Amino acid sequences of fusion polypeptides for mutants Ia, 2b, 3d, 4d, 5b and 6c.
- E Amino acid sequences of 29-mer polypeptides of mutants Ia, 2b, 3d, 4d, 5b and 6c.
- Figure 2 shows the expression and purification of the open cyclic permutant of kalata Bl.
- A SDS-PAGE analysis of the expression level. Lanes 1-3 are the Amersham protein molecular weight marker and the cell extract obtained before and after IPTG induction, respectively.
- B Lanes 1-3 are, respectively, the Amersham protein molecular weight standard, the synthetic His 6 -tagged thioredoxin-open cyclic permutant of kalata Bl fusion polypeptide, and the His 6 -tagged thioredoxin as cleavage product.
- FIG. 3 shows the cleavage of synthetic open cyclic permutant of kalata Bl from the fusion polypeptide by enterokinase.
- 40 ⁇ l of reactant solution containing 40 ⁇ g of the fusion polypeptide with 0.5 unit of enterokinase was incubated at 25°C.
- Lanes 3-8 were from samples obtained after 1, 5, 10, 30, 60, and 120 min of incubation, respectively.
- B Same as (A) except that 0.2 M dithiothreitol was included in the reaction mixture;
- C Same as (A) but in the presence of 0.2 M hydrogen peroxide.
- Figure 4 shows RP-HPLC chromatograms of the open cyclic permutant of kalata Bl.
- A A typical chromatogram of a synthetic open cyclic permutant of kalata Bl in its fully oxidized form.
- B A typical chromatogram of a synthetic open cyclic permutant of kalata Bl in its fully reduced form.
- Figure 5 shows the LCMS (A) and MALDI-TOF (B) data for confirmation of the identity of the open cyclic permutant of kalata Bl .
- Figure 6 shows the LCMS and MALDI-TOF data for confirmation of the identity of (A) mutant Ia; (B) mutant 2b; (C) mutant 3d; (D) mutant 4d; (E) mutant 6c.
- Figure 7 shows inhibitory effect of an open cyclic mutant of kalata Bl on the dengue virus NS2B/NS3 protease.
- Lane 1 Molecular weight standard from Amersham; Lane 2: thioredoxin-NS2B/NS3 without any treatment; Lane 3: thioredoxin-NS2B/NS3 with enterokinase and PBS buffer as control; Lane 4: thioredoxin-NS2B/NS3 with enterokinase treated with an open cyclic permutant of kalata Bl; Lane 5: thioredoxin- NS2B/NS3 with enterokinase treated with the open cyclic mutant Ia; Lane 6: thioredoxin- NS2B/NS3 with enterokinase treated with water.
- the cDNA sequence of kalata Bl was obtained and codon-optimized using back translation tools of Entelechon GmBH (Letol.O).
- Any expression vector suitable for expression of the target polynucleotide may be used.
- vectors include the pET series from Novagen, the pQE series from Qiagen, and pBR322 in the case in which Escherichia coli serves as a host and pUBl 10 in the case in which Bacillus subtilis serves as a host.
- the lac or tac promoter commonly used for inducing the expression of fused or unfused gene products, may be inserted into the vector.
- the T7 promoter may be used.
- a polynucleotide sequence encoding a fusion partner containing a tag may be cloned downstream of and in operable linkage with the promoter. This sequence may contain the translational start codon ATG.
- the sequence coding for the cleavage recognition site may be inserted between the fusion partner and target polypeptide encoding sequences. Multiple restriction sites for the insertion of the target gene may be present downstream of the fusion partner. It is preferable to maintain the number of sites in the multiple cloning region (MCR) to a minimum.
- a nucleotide sequence coding for a translation termination codon, in all 3 reading frames, may be inserted downstream of the target polypeptide encoding sequence.
- a sequence encoding the target polypeptide of the present invention maybe inserted in the multiple cloning site in the appropriate reading frame.
- an oligonucleotide containing the coding sequence of the open cyclic kalata Bl polypeptide (Fig. IA) was artificially synthesized with 13 silent codon changes made according to E. coli codon preference.
- ⁇ ET32a Novagen
- 5' BgI II and 3' Sal I sites were incorporated by PCR amplification of the synthetic DNA.
- the 5' primer also contained a 15-bp sequence encoding an enterokinase recognition site downstream of the BgII restriction recognition sequence.
- Directional insertion of the amplified product places the kalata Bl-coding sequence downstream of the thioredoxin.
- Fig. IB The resulting amino acid sequence of the expressed fusion polypeptide is shown in Fig. IB.
- the incorporated enterokinase recognition site allows separation of the open cyclic kalata Bl polypeptide (or a mutant thereof) from the fusion partner without leaving any unwanted residues on the 29-mer open cyclic kalata Bl polypeptide (or a mutant thereof) (Fig. 1C).
- the expression vector construct may be introduced into an appropriate host cell through conventional methods such as the protoplast method or the competent cell method.
- Host cells such as Gram-positive bacteria belonging to the genus Bacillus and Gram-negative bacteria such as Escherichia coil may be used. Selected strains of host cells are inoculated in a medium containing an assimilable carbon source, a nitrogen source and essential nutrients, and are cultured through conventional fermentation methods.
- an overnight culture of the transformed E. coli strain BL21 (DE3) with the expression vector was diluted in a ratio of 1 :25 into 100 mL of growth medium (LB medium containing 100 ug/mL of ampicillin). The culture was incubated at 37°C until its optical density at 600nm was 0.6. The polypeptide expression was induced by the addition of 1 mM isopropyl-1-thio-p-D-galactoside (IPTG) for 3 h.
- IPTG isopropyl-1-thio-p-D-galactoside
- Collection and purification of a target polypeptide from the thus-obtained culture broth can be performed according to conventional methods applicable to the collection and purification of common proteins.
- cells are separated from the culture broth by centrifugation or filtration, and the target polypeptide can be obtained from the supernatant through conventional purification procedures, examples of which include: fractionation on an ion-exchange column; ethanol precipitation; affinity chromatography; ultracentrifugation; reverse phase HPLC; chromatography on silica or on a cation- exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; protein A Sepharose columns to remove contaminants such as IgG; and metal chelating columns to bind polyhistidine-tagged forms of polypeptides.
- the transformed cells after lysis, and fractionation into the soluble and the insoluble fractions, can be analyzed to determine the solubility of the fusion polypeptide.
- the fusion polypeptide When the fusion polypeptide is produced in an insoluble form, it is present in the form of inclusion bodies.
- the insoluble pellet which contains the inclusion bodies is washed in a buffer containing sodium phosphate, DPT, and Triton X-100. The contaminating components are thereby removed, leaving the inclusion bodies containing the target polypeptide in the insoluble pellet.
- the full-length polypeptide can be purified using affinity column chromatography, depending on the type of purification tag in the fusion partner fused to the target polypeptide.
- the cell pellet was harvested and resuspended in PBS buffer. After sonication, the resulting cell lysate was cleared of bacterial debris by ultracentrifugation.
- the fusion polypeptide with a His 6 -tagged thioredoxin was absorbed onto a Nickel-charged metal affinity column made from chelating sepharose (Qiagen). The polypeptide was eluted from the column using 300 mM of imidazole. The purity and quantity of the fusion polypeptide was examined by SDS-PAGE and using a BCA (bicinchoninic acid) protein assay kit (Pierce). For the SDS-PAGE analysis, the fusion polypeptide was electrophoresed on a 12% SDS-polyacrylamide gel and quantitatively analyzed using a BioRad GS-800 scanning densitometer.
- the cleavage of purified fusion polypeptides with enzymatic or chemical cleavage reagents may be conducted by dissolving the fusion polypeptide, e.g., in a suitable buffer such as Tris buffer or phosphate buffer (e.g., especially at a pH of 6-9), depending on the solubility properties of the particular fusion polypeptide involved.
- a suitable buffer such as Tris buffer or phosphate buffer (e.g., especially at a pH of 6-9), depending on the solubility properties of the particular fusion polypeptide involved.
- the cleavage reagent(s) and oxidant are added to the solution and incubation ensues at a temperature and time optimized, e.g., by routine, conventional experiments, generally 25°C-40°C, for 0.5-10 hours.
- the fusion polypeptide preparation obtained from metal chelating affinity chromatography was subjected to buffer change to PBS buffer using Vivaspin ultrafiltration spin columns with a molecular weight cut-off of 30,000 Dalton (Vivascience).
- the resulting polypeptide solution was treated with enterokinase to release the 29-mer synthetic polypeptide.
- 40 ⁇ l of reactant solution containing 40 ⁇ g of the fusion polypeptide with 0.5 unit of enterokinase (Novagen) was incubated at 25 0 C overnight.
- the efficiency of the cleavage reaction was monitored by SDS-PAGE analysis by monitoring the densitometric changes of the fusion polypeptide band at 22 kDa.
- the target polypeptide with a molecular weight of 2.9 kDa in size could not be visualized in conventional SDS-PAGE. However, it could easily be detected and analyzed with reversed-phase HPLC.
- the reactant solution after enterokinase cleavage contains several polypeptides including thioredoxin, enterokinase, the 29-mer target polypeptide along with a number of less abundant non-specific cleavage products.
- thioredoxin enterokinase
- the 29-mer target polypeptide contains several polypeptides including thioredoxin, enterokinase, the 29-mer target polypeptide along with a number of less abundant non-specific cleavage products.
- ultrafiltration spin columns with MWCO 10000 Dalton Vivaspin 500 from Vivascience
- the ultrafiltration was performed by centrifugation at 300Og for 30 minutes.
- the effectiveness of the separation of the target polypeptide from His 6 -tagged thioredoxin was monitored using SDS-PAGE and HPLC analyses.
- the concentration of the protein solution obtained was examined using a BCA protein assay kit (Pierce).
- RP-HPLC reversed-phase high performance liquid chromatography
- a Shimadzu LC-lOAvp series apparatus with a UV detector and a VP-ODS CIS column (250.0 x 4.6 mm, 5 ⁇ m, 300A).
- a gradient was achieved using buffer A (containing 0.05% trifluoroacetic acid in water) and buffer B (containing 80% acetonitrile and 0.05% trifluoroacetic acid in water).
- the flow rate was 1 mL/min with buffer B being increased from 0% to 90% in 40 minutes.
- the chromatograms were recorded at a wavelength of 220 nm and the data analysed using LCsolution Version 1.0 (Shimadzu).
- the collected fractions were either used directly for mass spectrometric (MS) analysis or dried on a Speedvac concentrator (Braun) and reconstituted in PBS buffer for other activity assays.
- MS mass spectrometric
- Braun Speedvac concentrator
- Mass spectrometric analysis was carried out using Shimadzu LCMS-2010 AJEV and Axima-CFRP/r ⁇ (MALDI-TOF) systems. Separation in the LCMS was performed on a VP-ODS column (250.0 x 2.0 mm), in a 40 0 C oven, with a mobile phase of 70% acetonitrile in water containing 0.1% formic acid having a flow rate of 0.2mL/min in isocratic mode. The target polypeptide was reconstituted for MS analysis in the same PBS buffer used in the enterokinase cleavage reaction.
- the LCMS interface conditions were as follows: interface and operation mode: ESI, scan, m/z 600-4600; probe temperature: room temperature; CDL temperature: 250 0 C (desolvation); block temperature: 200 0 C; nebulizing gas flow: N 2 , 1.5 L/min; drying gas:N 2 , 10 L/min.
- the MALDI-TOF conditions were as follows: matrix: CHCA, 10 mg/mL in MeCN/Water (1:1) with 0.05% TFA; analysis conditions: positive reflectron mode.
- the mixtures were incubated at 37°C for 1 hr to overnight, after which the reactions were terminated by adding 500 ⁇ l of 5% TCA.
- the mixtures were vortexed briefly and incubated at 37 0 C for a further 10 mins.
- the TCA precipitate was removed by centrifugation at 12,00Og for 5 minutes while 400 ⁇ l of the supernatant was mixed with 600 ⁇ l of assay buffer.
- the absorbance was read against the reagent blank using a UV- spectrometer at 492 nm or a Fluorometer with excitation wavelengths of 490 ran and emission wavelengths of 525 nm.
- the buffer was prepared by mixing 20 mL of 100 mM Tris (pH 8.0) with 100 mL of 600 mM sodium chloride and the volume made up to 200 mL with distilled water. A lO mM solution of BAPNA and a 10% v/v positive control for the protease was prepared. Initial concentrations of lOO ⁇ g/mL and 65.5 ⁇ g/mL for the NS2B/NS3 and NS3 proteases, respectively, were concentrated using a Vivaspin column to 0.1 mg/mL and 0.0655 mg/mL, respectively. Reaction mixtures were prepared according to Tables 3 and 4 below.
- reaction mixtures were incubated at 23 0 C for two time intervals of 3 hrs and 24 hrs before measuring the absorbance at 405 nm.
- the inhibition is specific and only targets the NS2B/NS3 protease activity, it should lead to the inhibition of the autolytic cleavage of NS2B/NS3 and should not interfere or inhibit the subsequent enterokinase cleavage of NS2B/NS3 from the full-length thioredoxin-NS2B/NS3 fusion polypeptide. Effectiveness and specificity of the mutant molecule can be evaluated by comparing the profile and level of inhibition of the autocatalytic activity of NS2B/NS3 and the proteolytic activity of enterokinase.
- reaction mixture was withdrawn and assayed on SDS-PAGE.
- the profile of products including the percentage of uncleaved NS2B/NS3 was monitored by measuring the densitometric changes of the uncleaved NS2B/NS3 at 20-25 kDa on SDS-PAGE.
- the cDNA sequence encoding the 29-mer open cyclic permutant of kalata B l was synthesized and fused in-frame to His 6 -tagged thioredoxin in the bacterial expression vector, pET32a.
- the fusion polypeptide was overexpressed in the bacterial host, E. coli strain BL21 (DE3).
- the fusion polypeptide was secreted into the cytoplasm as a soluble protein with an apparent molecular weight of 22 kDa based on SDS-PAGE analysis (Fig. 2). Scanning densitometric analysis revealed that the fusion polypeptide was overexpressed at a level that accounts for approximately 30% of total cellular proteins.
- soluble fusion polypeptide Up to 20 mg of soluble fusion polypeptide could be obtained from 1 litre of bacterial culture. Optimal expression of the fusion polypeptide was achieved when the culture was carried out at 37°C and the induction was performed with IPTG at a concentration of 1 mM.
- a metal chelating Sepharose column was employed to remove cellular proteins while the absorbed His 6 -tagged thioredoxin-open cyclic permutant of kalata Bl fusion polypeptide was eluted from the column using imidazole (30OmM).
- the purity and identity of the fusion polypeptide was assayed by polyacrylamide gel electrophoresis and staining using Pierce GelCode blue stain reagent.
- the yield and concentration of the fusion polypeptide solution were determined using the BCA protein assay.
- a fusion polypeptide solution with a purity of over 95% and a final concentration of 2 to 3 mg/mL in PBS buffer can be obtained using Vivaspin ultrafiltration columns for concentration and buffer exchange.
- cysteine-rich polypeptides can be efficiently produced with high yields in a bacterial host using an optimized cDNA sequence.
- an enterokinase recognition sequence was introduced immediately upstream of the target polypeptide, allowing the latter to be released without leaving any unwanted residues upon treatment with enterokinase.
- the cleavage reaction is typically performed overnight at 25°C.
- the cleavage reaction was monitored by SDS-PAGE analysis by observing the disappearance of the fusion polypeptide band at 22 kDa (Fig. 3).
- the target polypeptide with molecular weight of 2.9 kDa in size is not detectable in conventional SDS-PAGE analysis. However, it can be easily monitored on reversed-phase HPLC as described below.
- the reactant solution from enterokinase cleavage contains mainly four peptide entities including the enterokinase, the remnant uncleaved fusion polypeptide, the His 6 -tagged thioredoxin fusion partner and the target polypeptide, the open cyclic permutant of kalata Bl, which have molecular weights of 26, 22, 19 and 2.9 kDa, respectively.
- the molecular weight of the target polypeptide, the open cyclic permutant of kalata Bl is at least 16 kDa smaller than that of the other three peptide entities in the reactant solution, thus facilitating its separation by centrifugal ultrafiltration using a semipermeable membrane.
- thioredoxin normally functions as a disulphide reductant under physiologically neutral conditions such as those in a PBS buffer.
- thioredoxin has a highly conserved dithiol motif (-Cys-Gly-Pro-Cys-) as active site for regulating redox reactions. It normally functions as a reducing agent for reduction of disulphide bonds to yield thiol groups.
- Mutant Ia has a molecular weight of 2954.3 (Fig. 6A); mutant 2b a molecular weight of 2913.7 (Fig. 6B); mutant 3d a molecular weight of 2911.5 (Fig. 6C); mutant 4d a molecular weight of 2909.3 (Fig. ⁇ D); mutant 6c a molecular weight of 2775.8 (Fig. 6E). It can be seen that the molecular weights of mutants 2b, 3d and 4d correspond closely to the theoretical molecular weight of the open cyclic permutant of kalata Bl in its fully oxidized form (2910) indicating close structural similarities.
- Fig. 7 shows typical results of an activity inhibition assay of the synthetic mutant Ia on dengue NS2B/NS3 protease activity.
- the intensity of the band for the uncleaved NS2B/NS3 polypeptide at 20-25 kDa was higher in the presence of the mutant Ia (Lane 5, Fig. 7) or the open cyclic permutant of kalata Bl (Lane 4, Fig. 7); hence, autocleavage of the NS2B/NS3 polypeptide was inhibited by the mutant Ia and the open cyclic permutant of kalata Bl.
- the intensity of the band for the uncleaved NS2B/NS3 polypeptide at 20-25 kDa in the control reactions was lower due to autocatalytic cleavage of the NS2B/NS3 polypeptide in the absence of the inhibitor (i.e. the mutant Ia or the open cyclic permutant of kalata Bl).
- the disclosed 29-mer open cyclic permutant of kalata Bl or its mutants can be overexpressed using a synthetic codon-optimised cDNA sequence in a fusion polypeptide and readily purified by affinity chromatography using metal chelating sepharose. Subsequent cleavage of the fusion polypeptide yields the 29-mer polypeptide that can then be readily purified from the enterokinase cleavage reactant solution, followed by centrifugal ultrafiltration through a semipermeable membrane. Further purification of the 29-mer polypeptide can be readily achieved by applying reversed-phase high performance liquid chromatography.
- open cyclic mutants of naturally occurring cyclic polypeptides in fully oxidized and functional form, can be readily produced and purified cost-effectively and in high yield, which are important criteria for use of such molecules in pharmaceutical applications such as in anti-viral treatment.
- the anti-dengue activity of the open cyclic mutants possess higher levels of inhibitory activity on the dengue NS3 protease and therefore provides a higher level of potency when used in anti-viral treatment Levels of such activity can furthermore be easily and specifically assayed quantitatively using the disclosed protease activity assay.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0900707A GB2453084A (en) | 2006-06-19 | 2007-06-19 | Novel polypeptides for an anti-viral treatment |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG200604180-0A SG138488A1 (en) | 2006-06-19 | 2006-06-19 | Novel polypeptides for anti-viral treatment |
SG200604180-0 | 2006-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007149052A1 true WO2007149052A1 (en) | 2007-12-27 |
Family
ID=38833697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SG2007/000168 WO2007149052A1 (en) | 2006-06-19 | 2007-06-19 | Novel polypeptides for anti-viral treatment |
Country Status (3)
Country | Link |
---|---|
GB (1) | GB2453084A (en) |
SG (1) | SG138488A1 (en) |
WO (1) | WO2007149052A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3431095A1 (en) * | 2011-12-22 | 2019-01-23 | Medizinische Universität Wien | Cyclotides as immunosuppressive agents |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001027147A1 (en) * | 1999-10-13 | 2001-04-19 | The University Of Queensland | A novel molecule |
WO2001034829A2 (en) * | 1999-11-05 | 2001-05-17 | The University Of Queensland | Nucleic acid sequence which encodes for an amino acid sequence capable of being cyclized within a cell or cell membrane |
-
2006
- 2006-06-19 SG SG200604180-0A patent/SG138488A1/en unknown
-
2007
- 2007-06-19 GB GB0900707A patent/GB2453084A/en not_active Withdrawn
- 2007-06-19 WO PCT/SG2007/000168 patent/WO2007149052A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001027147A1 (en) * | 1999-10-13 | 2001-04-19 | The University Of Queensland | A novel molecule |
WO2001034829A2 (en) * | 1999-11-05 | 2001-05-17 | The University Of Queensland | Nucleic acid sequence which encodes for an amino acid sequence capable of being cyclized within a cell or cell membrane |
Non-Patent Citations (1)
Title |
---|
DALY N. ET AL.: "The role of the cyclic peptide backbone in the anti-HIV activity of the cyclotide kalata B1", FEBS LETTERS, vol. 574, no. 1-3, 2004, pages 69 - 72, XP004557239, DOI: doi:10.1016/j.febslet.2004.08.007 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3431095A1 (en) * | 2011-12-22 | 2019-01-23 | Medizinische Universität Wien | Cyclotides as immunosuppressive agents |
US10357537B2 (en) | 2011-12-22 | 2019-07-23 | Medizinische Universitat Wien | Cyclotides as immunosuppressive agents |
Also Published As
Publication number | Publication date |
---|---|
GB2453084A (en) | 2009-03-25 |
GB0900707D0 (en) | 2009-03-04 |
SG138488A1 (en) | 2008-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210284698A1 (en) | Stabilized soluble pre-fusion rsv f polypeptides | |
Heimann et al. | Core protein of pestiviruses is processed at the C terminus by signal peptide peptidase | |
JP4423542B2 (en) | Antibacterial polypeptide and use thereof | |
ES2213861T3 (en) | PROCEDURE FOR OBTAINING ACTIVE NGF-BETA. | |
ITMI20130992A1 (en) | IALURONIDASI BACTERIA AND METHOD FOR ITS PRODUCTION | |
CN113383015A (en) | Recombinant protein variants | |
Hou et al. | The truncated human beta-defensin 118 can modulate lipopolysaccharide mediated inflammatory response in RAW264. 7 macrophages | |
CN105555300A (en) | Compositions and methods for treating celiac sprue disease | |
Li et al. | Siganus oramin recombinant L-amino acid oxidase is lethal to Cryptocaryon irritans | |
JPH0436185A (en) | Fused antigen polypeptide | |
Liew et al. | The legumain McPAL1 from Momordica cochinchinensis is a highly stable Asx-specific splicing enzyme | |
US20130085111A1 (en) | Production of human c1 inhibitor in human cells | |
Kwon et al. | Recombinant adenylate kinase 3 from liver fluke Clonorchis sinensis for histochemical analysis and serodiagnosis of clonorchiasis | |
WO2007149052A1 (en) | Novel polypeptides for anti-viral treatment | |
Zhang et al. | Enzyme activity of Schistosoma japonicum cercarial elastase SjCE-2b ascertained by in vitro refolded recombinant protein | |
Andreánsky et al. | High-level expression of enzymatically active bovine leukemia virus proteinase in E. coli | |
Eliseev et al. | High-yield expression and purification of p18 form of Bax as an MBP-fusion protein | |
KR102064810B1 (en) | N-terminal fusion partner for preparing recombinant polypeptide and method of preparing recombinant polypeptide using the same | |
Bell et al. | The N-terminus of PE2 in Sindbis virus-infected cells | |
van der Weyden et al. | Acanthoxin, a toxic phospholipase A2 from the venom of the common death adder (Acanthophis antarcticus) | |
JP2798573B2 (en) | Natural polypeptide having human neutrophil elastase inhibitory activity and pharmaceutical preparation containing the same | |
Ishino et al. | Comparison of NSP4 protein between group A and B human rotaviruses: detection of novel diarrhea-causing sequences in group B NSP4 | |
JP5614477B2 (en) | SARS3CL protease recombinant protein | |
KR102011291B1 (en) | Novel fusion polypeptide and method of preparing human parathyroid hormone 1-34 using the same | |
KR102009709B1 (en) | Method of preparing human parathyroid hormone 1-84 using fusion polypeptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07748713 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 0900707 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20070619 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 0900707.1 Country of ref document: GB |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07748713 Country of ref document: EP Kind code of ref document: A1 |